NEW YORK (GenomeWeb News) – NeoGenomics today reported third-quarter revenue growth of 26 percent year over year.

For the three months ended Sept. 30, the Ft. Meyers, Fla.-based cancer genetic testing firm said that revenues rose to $14.2 million from $11.3 million a year ago. The number of tests performed in the quarter increased to 28,315 from 19,977, but the average revenue per test dipped to $501.58 from $566.66.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A panel at the New York Times discusses anonymity and privacy of users of 23andMe's services when access to its database is offered for research.

National Institutes of Health Director Francis Collins appears before a House subcommittee to discuss his agency's budget request.

In PNAS this week: Akt3 amplification in glioma progression, Tibetan Plateau frog genome, and more.

The US Supreme Court has declined to review a decision involving the use of "inadvertently shed" DNA in a police investigation and subsequent conviction.